ImmunoGen Balance Sheet - Quarterly (NASDAQ:IMGN)

Add to My Stocks
$7.38 $0.3 (3.91%) IMGN stock closing price Oct 12, 2018 (Closing)

A thorough fundamental analysis involves using data from ImmunoGen balance sheet, apart from other financial statements, to value the business. Balance sheet items like cash at hand, total assets and liabilities helps one analyze a company and summarize the financial performance of the company like we have in our ImmunoGen stock analysis. Quarterly results are typically accompanied with the company releasing financial statements. ImmunoGen had a long term debt of $- at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at ImmunoGen operating cash flow and ImmunoGen revenue also. ImmunoGen debt to equity ratio is .

View and download ImmunoGen quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Marketable Securities---------
Raw Materials---------
Work In Progress1.89M--2.11M3.35M3.1M1.83M1.83M-
Finished Goods---------
Notes Receivable---------
Other Current Assets9.89M9.72M2.96M4.74M4.75M6.39M5.38M7.48M6.55M
Total Current Assets
Property Plant & Equipment--71.98M---72.34M-73.3M
Accumulated Depreciation--57.44M---52.84M-50.6M
Net Property Plant & Equipment
Investment & Advances---------
Other Non-Current Assets---------
Deferred Charges--------6.17M
Deposits & Other Assets4.43M4.68M3.79M3.11M3.14M3.19M3.02M3.13M3.43M
Total Assets
Notes Payable---------
Accounts Payable12.88M7.78M8.56M6.61M5.15M5.1M7.89M8.97M11.51M
Current Portion Long-Term Debt---------
Current Portion Capital Leases---------
Accrued Expenses26.38M29.42M27.24M22.48M19.54M17M18.09M16.76M20.43M
Income Taxes Payable---------
Other Current Liabilities24.07M29.01M19.96M44.56M42.65M18.26M29.78M30.48M29.49M
Total Current Liabilities
Deferred Taxes/Income85.55M86.45M98.88M99.15M24.43M24.71M25M25.27M25.52M
Convertible Debt2.05M2.05M2.05M3.02M97.29M97.13M96.96M96.79M100M
Long-Term Debt---------
Non-Current Capital Leases---------
Other Long-Term Liabilities140.93M146.54M155.87M161.15M165.52M168.64M173.97M175.59M182.42M
Total Liabilities
Minority Interest---------
Preferred Stock---------
Common Stock Net1.49M1.33M1.32M1.15M-----
Capital Surplus1.18B1.02B1.01B903.01M784.65M781.49M778.84M775M770.51M
Retained Earnings-1.09B-1.05B-1.03B-1.02B-958.78M-949.91M-932.57M-898.41M-853.68M
Treasury Stock---------
Other Liabilities---------
Shareholders Equity89.19M-36.31M-17.89M-111.29M-173.22M-167.53M-152.85M-122.53M-82.3M
Total Liabilities & Shareholders Equity381.08M264.96M294.67M225.69M181.37M163.32M198.86M231.34M287.08M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the ImmunoGen stock price, and ImmunoGen historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the ImmunoGen PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like ImmunoGen owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for IMGN stock as of 2018 Q2 is $381.08M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities: The total liabilities of ImmunoGen for the quarter 2018 Q2 total to $291.89M. Liabilities for a company like ImmunoGen include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

ImmunoGen Balance Sheet - Key Ratios

Quarterly Balance Sheets For ImmunoGen, Inc. Peers

Amgen balance sheet, Seattle Genetics balance sheet, Takeda Pharma balance sheet